Antibiotics in Fight Against MRSA Superbug Show Promise

by Rajashri on October 29, 2008 at 2:24 PM
 Antibiotics in Fight Against MRSA Superbug Show Promise

Researchers have confirmed that two experimental antibiotics from the United States and Switzerland have shown promising results in fighting the methicillin-resistant staphylococcus aureus (MRSA) superbug.

US pharmaceutical Paratek said on Sunday a new class of antibiotic it has developed called PTK 0896 was 98 percent efficient in countering MRSA - 5.0 percent more efficient than rival Pfizer's Zyvox drug - according to its phase ii clinical trial on 234 patients,


Switzerland's bio-pharmaceutical company Arpida said its Iclaprim drug administered intravenously was able to cure MRSA infection in 92.3 percent of patients.

Arpida recently submitted Iclaprim to approval by the US Food and Drug Administration. Company president Jurgen Raths said he expected FDA approval for the drug in January.

MRSA has shot to prominence in recent years as many people catch the bug while being treated in hospitals - leading to doctors in Britain being banned from wearing their traditional white coats in favour of plastic aprons in a bid to reduce the risks of transmission.

In the United States, MRSA is the cause of more than 60 percent of all hospital infections. According to the Centers for Disease Control and Preventions, MRSA in 2005 infected 94,000 people and killed 19,000 in the United States.

Despite Sunday's announced developments in fighting MRSA, some scientists were not optimistic and said the medical community was still basically powerless against the deadly bug.

"Most of these compounds are from classes that we already knew about, which is disappointing," Johnson and Johnson Pharmaceutical Research and development chief Karen Bush told the 48th annual Interscience Conference on Antimicrobial Agents held this weekend in Washington.

She said there were antibiotics-resistant MRSA strains still "circulating and we cannot find any drugs that are working against them. So I still believe we have a major challenge."

Dr. Michael Scheld, of the University of Virginia School of Medicine, said "there is almost nothing in the pipeline now ... We as clinicians have nothing that we can obtain to treat these multidrug-resistant organisms for least probably five to 10 years."

Paratek Pharmaceutical researcher Robert Arbeit said the medical community needed "new paradigms that includes the concept of prevention as well as treatment."

"That approach of trying to prevent those organisms from getting established ... by a classic vaccine approach ... or by just giving another antibiotic ... that doesn't work very well because that organism will eventually" become resistant.

"But this idea of trying to prevent infection by going at the mechanism of the organism, I think that's the kind of paradigm shift we need."

Source: AFP
Font : A-A+



Recommended Readings

Latest Research News

Confronting the Painful Realities of Racial Bias in Health
Painful realities of racial discrimination and bias are increasingly acknowledged as harmful to the well-being.
Intricate Dance of Flaxseed, Gut Microbiome, and Breast Cancer Genes
Role of flaxseed in the relationship between gut microorganisms and mammary gland microRNAs has been uncovered by a new study.
MRNA Therapy's Promise for Chronic and Acute Liver Disease
New mRNA stem cell therapy, akin to COVID-19 vaccine tech, shows potential against chronic and acute liver diseases.
Could Light Therapy Be a Breakthrough for Alzheimer's?
Light therapy enhances sleep and psycho-behavioral symptoms in Alzheimer's patients with minimal side effects.
Does Twice Daily Stimulation Enhance Alzheimer's Mental Functions?
Electrical stimulation improves Alzheimer's patients' cognitive function and correlates with restored cortical plasticity.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Antibiotics in Fight Against MRSA Superbug Show Promise Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests